Recombinant Human Ephrin-A1 Fc Chimera Protein, CF Summary
Product Specifications
Human Ephrin-A1 (Met1-Ser182) Accession # P20827 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
6417-A1
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 100 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: Ephrin-A1
Ephrin-A1, also known as B61 and LERK-1, is a member of the Ephrin-A family of GPI-anchored ligands that bind and induce the tyrosine autophosphorylation of Eph receptors. Ephrin-A ligands are structurally related to the extracellular domains of the transmembrane Ephrin-B ligands. Eph-Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression (1, 2). Human Ephrin-A1 is synthesized with an 18 amino acid (aa) signal peptide, a 164 aa mature chain, and a 23 aa C‑terminal propeptide which is removed prior to GPI linkage of Ephrin-A1 to the membrane (3, 4). It can also be released as a soluble molecule (3, 5, 6). The mature 21 ‑ 25 kDa human Ephrin-A1 shares 85% aa sequence identity with mouse and rat Ephrin-A1. Alternate splicing generates an additional isoform that lacks 22 aa in the juxtamembrane region (7).
This short isoform is also expressed on the cell surface and exhibits weakened binding to EphA2 (7). Ephrin-A1 is widely expressed on endothelial and epithelial cells, particularly in the lung, intestine, liver, and skin (4, 8). It is expressed on resting CD4+ T cells but is down‑regulated following activation (9, 10). Ligation of Ephrin-A1 on CD4+ T cells inhibits cell proliferation and activation, although soluble Ephrin-A1 can promote T cell chemotaxis (9, 10). In cancer, Ephrin-A1 is expressed by tumor cells as well as on the tumor‑associated vasculature (5, 6, 11). It inhibits tumor cell proliferation and migration but also supports tumor growth by promoting angiogenesis (12 ‑ 14). Soluble Ephrin-A1 additionally promotes neuronal survival and neurite extension (15).
- Miao, H. and B. Wang (2009) Int. J. Biochem. Cell Biol. 41:762.
- Pasquale, E.B. (2010) Nat. Rev. Cancer 10:165.
- Holzman, L.B. et al. (1990) Mol. Cell. Biol. 10:5830.
- Shao, H. et al. (1995) J. Biol. Chem. 270:5636.
- Easty, D.J. et al. (1995) Cancer Res. 55:2528.
- Cui, X.-D. et al. (2010) Int. J. Cancer 126:940.
- Finne, E.F. et al. (2004) Biochem. J. 379:39.
- Takahashi, H. and T. Ikeda (1995) Oncogene 11:879.
- Wohlfahrt, J.G. et al. (2004) J. Immunol. 172:843.
- Aasheim, H.-C. et al. (2005) Blood 105:2869.
- Ogawa, K. et al. (2000) Oncogene 19:6043.
- Liu, D.-P. et al. (2007) Int. J. Oncol. 30:865.
- Brantley-Sieders, D.M. et al. (2006) Cancer Res. 66:10315.
- Pandey, A. et al. (1995) Science 268:567.
- Magal, E. et al. (1996) J. Neurosci. Res. 43:735.
Citations for Recombinant Human Ephrin-A1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
16
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Replicating infant-specific reactive astrocyte functions in the injured adult brain
Authors: L Teo, AG Boghdadi, J Homman-Lud, IC Mundinano, WC Kwan, JA Bourne
Progress in neurobiology, 2021-06-17;0(0):102108.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
Authors: J Jukonen, L Moyano-Gal, K Höpfner, EA Pietilä, L Lehtinen, K Huhtinen, E Gucciardo, J Hynninen, S Hietanen, S Grénman, PM Ojala, O Carpén, K Lehti
Scientific Reports, 2021-04-23;11(1):8856.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling
Authors: H Wang, W Hou, A Perera, C Bettler, JR Beach, X Ding, J Li, MF Denning, A Dhanarajan, SJ Cotler, C Joyce, J Yin, F Ahmed, LR Roberts, W Qiu
Cell Reports, 2021-02-23;34(8):108765.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC
Authors: C Volz, S Breid, C Selenz, A Zaplatina, K Golfmann, L Meder, F Dietlein, S Borchmann, S Chatterjee, M Siobal, J Schöttle, A Florin, M Koker, M Nill, L Ozreti?, N Uhlenbrock, S Smith, R Büttner, H Miao, B Wang, HC Reinhardt, D Rauh, M Hallek, A Acker-Palm, LC Heukamp, RT Ullrich
Cell Rep, 2020-04-28;31(4):107568.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer
Authors: PC Lee, ST Chen, TC Kuo, TC Lin, MC Lin, J Huang, JS Hung, CL Hsu, HF Juan, PH Lee, MC Huang
Oncogene, 2020-01-31;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
EPH receptor A2 governs a feedback loop that activates Wnt/?-catenin signaling in gastric cancer
Authors: Q Peng, L Chen, W Wu, J Wang, X Zheng, Z Chen, Q Jiang, J Han, L Wei, L Wang, J Huang, J Ma
Cell Death Dis, 2018-11-19;9(12):1146.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
Authors: S Gu, WY Fu, AKY Fu, EPS Tong, FCF Ip, X Huang, NY Ip
Sci Rep, 2018-05-09;8(1):7377.
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay -
Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer
Authors: M Chu, C Zhang
Sci Rep, 2018-01-24;8(1):1539.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Ephrin-A1-EphA4 signaling negatively regulates myelination in the central nervous system
Authors: M Harboe, J Torvund-Je, K Kjaer-Sore, LS Laursen
Glia, 2018-01-19;0(0):.
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay -
EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/maturation and promote cell adhesion and protrusion formation in HL60 monocytes
Authors: M Mukai, N Suruga, N Saeki, K Ogawa
BMC Cell Biol., 2017-08-29;18(1):28.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
Authors: W Song, Y Hwang, VM Youngblood, RS Cook, JM Balko, J Chen, DM Brantley-S
Oncogene, 2017-06-05;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Bioassay -
A Modified Adenovirus Vector-Mediated Antibody Screening Method Identifies EphA2 as a Cancer Target
Authors: T Tanaka, H Yamada, M Kuroki, S Kodama, K Tamura, Y Takamatsu
Transl Oncol, 2017-05-12;10(4):476-484.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
Authors: Lennon F, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton P
J Biol Chem, 2014-07-14;289(35):24043-58.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion.
Authors: Sugiyama N, Gucciardo E, Tatti O, Varjosalo M, Hyytiainen M, Gstaiger M, Lehti K
J Cell Biol, 2013-04-29;201(3):467-84.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis.
Authors: Gordon K, Kochkodan J, Blatt H, Lin S, Kaplan N, Johnston A, Swindell W, Hoover P, Schlosser B, Elder J, Gudjonsson J, Getsios S
J Invest Dermatol, 2012-11-29;133(3):712-22.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
Nature, 2012-07-26;487(7408):505-9.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Ephrin-A1 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Ephrin-A1 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human Ephrin-A1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image